Prevalence and Sequelae of Computer Vision Syndrome in Egyptian Universities

Visual, Ocular Surface and Extraocular Diagnostic Criteria for Prevalence of Computer Vision Syndrome: A Cross-sectional Smart-survey Based Study

CVS-F4 questionnaire will be used as an instrument to survey CVS prevalence and severity among medical students

Study Overview

• Status: Completed
• Conditions: Computer Vision Syndrome
• Intervention / Treatment: Behavioral: CVS Group

Detailed Description

CVS-F4 (30 questions) will be an online survey via the SurveyMonkey Company. We will collect the responses and analyze the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. The questionnaire includes questions regarding potential ocular, extra-ocular, musclo-skeletal and neuro-psychatric complains caused by CVS. Complete statistical analysis of the survey data will be done using univariate and multivariate logistic and linear regression analysis. The CVS diagnosis will be based on the 5 diagnostic criteria (5DC) to create a new short self-assessment questionnaire for accurate prevalence of CVS.

• Study Type: Observational
• Enrollment (Actual): 8085

Contacts and Locations

Study Locations

• Egypt
  • Sohag, Egypt, 82425
    • Faculty of medicine
  • Sohag
    • Sohag,, Sohag, Egypt, 82425
      • Faculty of medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

medical students or staff who are using screens in their medical studies or personal lives and how these screens affect their medical studies and the effect of mandated medical computer use if present on their screen-behaviour and associated risk factor

Description

Inclusion Criteria:

• university students
• university staff members

Exclusion Criteria:

• ocular surgery
• amblyopia
• anisometropia
• strabismus
• systemic disease

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Control Group; The participants will respond to CVS-F4 questionnaire online via SurveyMonkey to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. This group will contains participants with no CVS complains.

Behavioral: CVS Group; CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants suffering from CVS	will be reported in form of percentage (%) of students with CVS	3 months
Rate of CVS symptoms-attacks	The results will be presented as annual percentage	3 months

Collaborators and Investigators

• Sponsor: Sohag University
• Investigators: Principal Investigator: Mohammed Iqbal, MD, PhD, Professor of Ophthalmology

Study record dates

Study Major Dates

• Study Start (Actual): December 30, 2021
• Primary Completion (Actual): May 20, 2022
• Study Completion (Actual): September 1, 2022

Study Registration Dates

• First Submitted: December 23, 2021
• First Submitted That Met QC Criteria: December 23, 2021
• First Posted (Actual): January 11, 2022

Study Record Updates

• Last Update Posted (Actual): May 29, 2024
• Last Update Submitted That Met QC Criteria: May 26, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Syndrome
• Other Study ID Numbers: Soh-Med-21-12-31

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No